BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

Mise à jour : Il y a 4 ans
Référence : NCT00367770

Femme et Homme

Extrait

This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology). Treatment duration is 6 months.


Critère d'inclusion

  • pulmonary arterial hypertension


Liens